Regulation of melatonin and neurotransmission in Alzheimer’s disease

Jaydeep Roy, Ka Chun Tsui, Jonah Ng, Man Lung Fung, Lee Wei Lim*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Citations (Scopus)

Abstract

Alzheimer’s disease is a neurodegenerative disorder associated with age, and is character-ized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles. Symptoms of AD include cognitive impairments, anxiety and depression. It has also been shown that individuals with AD have impaired neurotransmission, which may result from the accumulation of amyloid plaques and neurofibrillary tangles. Preclinical studies showed that melatonin, a monoaminergic neurotransmitter released from the pineal gland, is able to ameliorate AD pathologies and restore cognitive impairments. Theoretically, inhibition of the pathological progression of AD by melatonin treatment should also restore the impaired neurotransmission. This review aims to explore the impact of AD on neurotransmission, and whether and how melatonin can enhance neurotransmission via improving AD pathology.

Original languageEnglish
Article number6841
JournalInternational Journal of Molecular Sciences
Volume22
Issue number13
DOIs
Publication statusPublished - 1 Jul 2021
Externally publishedYes

Keywords

  • Alzheimer’s disease
  • Melatonin
  • Neurotransmission

Fingerprint

Dive into the research topics of 'Regulation of melatonin and neurotransmission in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this